MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance, leading to neuronal hyperpolarization and central nervous system depression.
| Metabolism | Hepatic via CYP3A4 oxidation; primary metabolite is α-hydroxymidazolam (active). |
| Excretion | Renal: ~80% as metabolites (primarily 1-hydroxymidazolam glucuronide), <1% unchanged; biliary/fecal: ~2-10% |
| Half-life | 2-6 hours (prolonged in elderly, obesity, hepatic impairment, or critical illness; up to 12 hours in ICU patients) |
| Protein binding | 96-98% bound to albumin |
| Volume of Distribution | 1-3 L/kg (increased in obesity, decreased in elderly or hypovolemia) |
| Bioavailability | Oral: ~40% (range 30-50%, extensive first-pass); IM: ~90%; intranasal: ~50-80% |
| Onset of Action | IV: 1-3 minutes; IM: 5-15 minutes; intranasal: 10-15 minutes; oral: 15-30 minutes |
| Duration of Action | IV: 2-6 hours (sedation); IM: 2-6 hours; oral: 3-6 hours (context-dependent; prolonged with continuous infusion or in hepatic/renal impairment) |
| Molecular Weight | 325.775 |
Initial: 0.5-2 mg IV over 2-3 min; titrate by 0.5-1 mg increments q2-3min as needed; usual total 2.5-5 mg. Continuous infusion: 0.02-0.1 mg/kg/hr IV (1-7 mg/hr). Intranasal: 0.2-0.3 mg/kg (max 15 mg).
| Dosage form | SOLUTION |
| Renal impairment | GFR 10-50 mL/min: decrease dose by 50% and monitor for prolonged sedation. GFR <10 mL/min: avoid or use extreme caution; reduce dose by 75%. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 30-50% and monitor. Child-Pugh C: reduce dose by 50-75%; consider alternative agent. |
| Pediatric use | IV sedation: 0.05-0.1 mg/kg over 2-3 min (max 2 mg); may repeat q2-3min (total up to 0.2 mg/kg). Intranasal: 0.2-0.3 mg/kg (max 10 mg). Oral: 0.25-0.5 mg/kg (max 20 mg) 30-45 min pre-procedure. |
| Geriatric use | Initial dose reduction by 30-50% (e.g., 0.5-1 mg IV slow); slower titration; monitor for hypotension and respiratory depression. |
| 1st trimester | Avoid unless essential; may cause congenital malformations, particularly neural tube defects and cardiac anomalies, especially with chronic or high-dose use. |
| 2nd trimester | Use only if benefit outweighs risk; may cause fetal growth restriction and neurobehavioral effects. |
| 3rd trimester | Avoid due to risk of neonatal withdrawal, respiratory depression, hypotonia, and feeding difficulties (floppy infant syndrome) especially near term. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Rapidly crosses the placenta with a fetal-to-maternal ratio of approximately 0.6-0.9; detectable in fetal blood and amniotic fluid. |
| Breastfeeding | Midazolam is excreted into breast milk in small amounts, but due to potential for accumulation and sedation in the infant, caution is advised. Monitor infant for drowsiness, poor feeding, and respiratory depression. Avoid use in lactating women unless clearly needed. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Inadequate human data; animal studies show increased fetal loss and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal withdrawal (floppy infant syndrome) and respiratory depression if used near term. Avoid prolonged or high-dose use. |
| Fetal Monitoring | Monitor maternal respiratory rate, oxygen saturation, and sedation level continuously during administration. Fetal heart rate monitoring recommended if used in labor. Neonatal monitoring for respiratory depression and hypotonia if used near delivery. |
| Fertility Effects | No human data on fertility effects. Animal studies show no significant impact on fertility at clinically relevant doses. |
■ FDA Black Box Warning
Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required.
| Common Effects | fluid replacement |
| Serious Effects |
Acute narrow-angle glaucomaUntreated open-angle glaucomaSevere respiratory insufficiency (e.g., COPD, sleep apnea)Myasthenia gravisKnown hypersensitivity to benzodiazepinesConcomitant use with other CNS depressants in non-ICU settings
| Precautions | Respiratory depression: monitor oxygen saturation and respiratory function, especially in elderly or debilitated patients, Hypotension: risk in hemodynamically compromised patients, Paradoxical reactions: restlessness, agitation, hostility (discontinue drug), Physical dependence and withdrawal: abrupt discontinuation may cause seizures and withdrawal syndrome, Use in pregnancy: risk of congenital malformations (reported in first trimester) and neonatal withdrawal (chronic use in later trimesters), Renal or hepatic impairment: reduce dose and monitor for prolonged sedation, Myasthenia gravis: may worsen muscle weakness, Severe COPD or sleep apnea: increased risk of respiratory depression, Intra-arterial injection: may cause arteriospasm and gangrene (avoid), Geriatric use: increased sensitivity, lower doses recommended |
| Food/Dietary | Grapefruit juice may increase midazolam levels via CYP3A4 inhibition; avoid concurrent use. No other significant food interactions. |
| Clinical Pearls | Midazolam in 0.9% sodium chloride is a short-acting benzodiazepine used for procedural sedation, anesthesia induction, and ICU sedation. It is water-soluble and can be administered IV or IM. Onset is rapid (1-3 min IV) with a short duration (15-30 min). Titrate to effect; monitor respiratory rate, oxygen saturation, and blood pressure. Flumazenil is the reversal agent. Avoid in acute narrow-angle glaucoma. Coadministration with opioids or other CNS depressants increases sedation and respiratory depression risk. Midazolam is metabolized by CYP3A4; inhibitors (e.g., azole antifungals, macrolides) prolong effects. Extravasation can cause tissue irritation. |
| Patient Advice | This medication causes drowsiness and dizziness; do not drive or operate machinery until fully recovered. · Avoid alcohol for at least 24 hours after administration. · Report any difficulty breathing, confusion, or unusual behavior to your healthcare provider immediately. · You may not remember events during the procedure (anterograde amnesia); this is expected and temporary. · If pregnant or breastfeeding, inform your doctor before use. |
Loading safety data…